To examine the use of long-term prophylactic mupirocin as part of a comprehensive strategy in reducing Staphylococcus aureus colonization and infection in a neonatal intensive care unit (NICU). STUDY DESIGN: Twice daily mupirocin was applied to all infants admitted to the NICU throughout hospitalization starting in 2004. S. aureus surveillance was implemented in 2008. The efficacy of these practices was evaluated with a retrospective review of infants admitted from 2004 to 2010 found to be colonized or infected with S. aureus. RESULT: During the study period, 66 of 6283 NICU infants had a S. aureus infection with 67% methicillin resistance. There were three distinctive S. aureus outbreaks, the first being a methicillin-resistant strain July 2004. After implementation of daily mupirocin, the outbreak was eradicated and the rate of S. aureus infection significantly decreased (1.82 to 0.40/1000 patient-days-at-risk, P ¼ 0.0049). Mupirocin was discontinued March 2005 followed by a methicillin-sensitive S. aureus outbreak November 2005. In December 2005, mupirocin was reinstituted and has continued to present day, again significantly reducing S. aureus infections (1.42 to 0.33/1000 patient-days-at-risk, Po0.0001) with zero isolates resistant to mupirocin. In the pre-mupirocin period, S. aureus colonization was upwards of 60% now with rates typically o5%. S. aureus colonization strongly predicted later invasive infection (Po0.0001). CONCLUSION: Although controversial, prophylactic mupirocin in all NICU infants has acted as a barrier to colonization and markedly decreased S. aureus infection rates over a 5-year period.
INTRODUCTION
Staphylococcus aureus is an important cause of infection in a neonatal intensive care unit (NICU) with outbreaks that are difficult to control, often requiring extensive and costly strategies for successful eradication. [1] [2] [3] [4] [5] A study in 2009 reported data from the National Nosocomial Infections Surveillance system stating that the incidence of S. aureus infections among US NICUs increased 13% in 10 years with a 300% increase in the incidence of methicillin-resistant S. aureus (MRSA). 6 Studies have shown that colonized patients are the chief source of S. aureus infection among high-risk populations with indistinguishable strains isolated first from the nares and then the blood. 1 Therefore, some units perform S. aureus surveillance as part of routine infection control practices or during an outbreak investigation to identify and isolate colonized infants to reduce the spread of Staphylococcus. 7, 8 Other units perform prophylaxis or decolonization measures to reduce S. aureus nasal carriage with the intent to reduce infection. The most commonly employed modality to eliminate S. aureus colonization after acquisition has been the use of intranasal mupirocin. 3, 4, 9, 10 Mupirocin has been found to significantly decrease S. aureus colonization in select populations. Additionally, mupirocin has also been used to control outbreaks but has only been used in short term periods for fear of inducing resistance or losing efficacy.
Staphylococcal infections and colonization have been recognized as hyperendemic in the general population of the Hawaiian Islands. Within our NICU at Kapi'olani Medical Center for Women and Children (KMCWC), we had two S. aureus epidemics, one methicillin-sensitive S. aureus epidemic in 1998 and one MRSA epidemic in 2002. During this 2002 outbreak, weekly S. aureus surveillance was briefly performed with colonization rates ranging from 15 to 60% with 30 to 60% MRSA. We also intermittently performed non-outbreak surveillance cultures showing an endemic colonization rate at times as high as 40% with a similar proportion of methicillin-resistant strains. In response to our third S. aureus outbreak in 2004, we instituted twice daily mupirocin application to the nares, umbilical stump, eroded skin and wounds of all infants admitted to the NICU throughout their hospitalization. For further control, we implemented S. aureus surveillance in 2008. Given the long-term use of universal mupirocin prophylaxis and S. aureus surveillance as part of a comprehensive strategy within our NICU, we performed the following retrospective study to examine S. aureus infection rates before and during the implementation of universal mupirocin as well as colonization rates after prolonged mupirocin exposure.
METHODS

Study population
This retrospective cohort study was conducted from 2004 through 2010 in the 60 bed, level IIIB NICU at KMCWC. 11 The KMCWC NICU is the referral center for the entire state of Hawai'i and much of the South Pacific, with a diverse patient population and a large proportion of outborn patients (10 to 20%). With the inability to close the unit to new admissions, KMCWC functions at or above capacity at all times with overcrowding a frequent concern. During the study period, there were B6200 live births, 900 NICU admissions and 150 very low birth weight (o1500 g) admissions per year. The NICU is divided into four pods, each with an open floor design with an overflow unit located on a different floor of the hospital.
Sequential performance improvement interventions
In response to a S. aureus outbreak in July 2004, KMCWC implemented twice daily mupirocin ointment to the nares, umbilical stump, eroded skin and wounds of all infants admitted to the NICU throughout their hospitalization. Only those infants with positive infection cultures were placed in isolation as surveillance screening was not otherwise performed at this time. Prophylactic mupirocin was discontinued in February 2005 due to concerns of inducing resistance. In November 2005, our NICU experienced another significant S. aureus outbreak. Therefore, in December 2005, as part of an ongoing quality improvement initiative, performance improvement teams adopted an intervention bundle based on recommendations from the Institute of Healthcare Improvement, the Vermont Oxford Network potentially better practices and internal expert discussions. This included reinstating the use of universal mupirocin as well as officially adopting the Institute of Healthcare Improvement central line bundle, which has been previously described in the literature, creating sepsis evaluation parameters and a renewed emphasis on handwashing technique. 12 With the exception of universal mupirocin, much of these infection control techniques were already routinely practiced in our NICU well before this period, however, it was decided that this comprehensive, standardized approach for proactive infection management would be beneficial. The performance improvement teams met monthly to review infection rates as part of continuous quality improvement Plan-Do-CheckAct cycles and in April 2008, the team implemented bimonthly active surveillance cultures of the nares of all infants admitted to the NICU. This surveillance was changed to weekly in November 2008 and then after a smaller S. aureus outbreak with rising S. aureus colonization rates in March 2009, surveillance cultures were added on admission in order to isolate infants who were colonized at birth. Once infants were found to be colonized with S. aureus, they no longer underwent surveillance screening and remained in isolation with cohorting when applicable throughout their hospitalization.
Study design and data collection
Eligible infants included all those with a positive S. aureus culture from January 2004 to December 2010 as identified via the hospital epidemiology MedMined database (Care Fusion). Patient data were collected via electronic medical records and included birth weight, gestational age, sex, mode of delivery, clinical condition at the time of positive culture and disposition. Details regarding S. aureus infections included the site of infection and metastatic complications defined as a distinct area of invasive infection such as abscess, cellulitis, septic arthritis/osteomyelitis, endocarditis or meningitis occurring in infants with S. aureus bacteremia. The antibiograms of the isolates were recorded and compared. Given the retrospective nature of this study, S. aureus isolates were not available for molecular typing. Therefore, we used the antimicrobial susceptibility patterns as a substitute for strain type during outbreak analysis. 13 
Definitions
Standard definitions were used for characterization of S. aureus infections as previously published and were based on clinical, laboratory, and radiographic findings when applicable.
14 Historically, it has been difficult for clinicians to distinguish 'complicated' or metastatic bloodstream infections (BSI) from 'uncomplicated' bacteremia. We used the standard definition as previously reported in the literature, that if a bloodstream infection was identified as a central line-associated bloodstream infection, this was considered the primary site of infection. 15 This laboratoryconfirmed bloodstream infection included clinical symptoms of sepsis and no other apparent source of infection at the time of diagnosis. A metastatic infection was considered when foci of invasive infections occurred during the treatment course. Metastatic infections identified within 24 h of the primary diagnosis were listed as 0 days to metastasis.
Surveillance cultures of the nares where plated on 5% sheep blood agar and placed into thioglycolate broth. Methicillin resistance was determined by analyzing the minimum inhibitory concentration to oxacillin and cefoxitin by the Vitek 2 System (Biomé rieux, Durham, NC, USA). Mupirocin resistance was determined using a mupirocin disk diffusion method with a 5-mg disk and a zone diameter breakpoint of 14 mm without differentiation of low-level or high-level resistance.
Statistical analysis w 2 -tests of association were used to assess whether colonization and infection rates were significantly associated with demographic factors such as sex, gestational age and birth weight and logistic regression models were used to estimate odds ratios (ORs). When incomplete patient characteristics were encountered, the patient was excluded from statistical analysis involving that characteristic. To avoid reverse causality bias of certain factors such as length of stay, our results are reported unadjusted. However, we ran additional statistical analyses controlling for time to colonization or infection as a surrogate to length of stay and these results are reported in the text. Wald w 2 P-values are presented for ORs. A statistical significance level of Po0.05 was used. The rate of S. aureus infection was calculated as the number of S. aureus infected neonates per 1000 patient-days-at-risk. Patient-days-at-risk was defined as the number of days of hospitalization for patients without S. aureus infection and the number of days between admission and the onset of infection in patients who were positive for S. aureus. Incidence rate ratios were determined to provide a relative measure of the effect of mupirocin in reducing S. aureus infection and were calculated as the incidence rate of infection during the mupirocin period divided by the incidence rate of infection during the control period. All analyses were conducted in SAS v. 9.2 (SAS Institute, Cary, NC, USA). To evaluate stability and special cause variation of the stepwise escalation in infection control management in the NICU, an analysis using a statistical process control U-chart was performed. A center line was calculated for each intervention with control limits set at 3 s.d. to minimize type I error.
RESULTS
S. aureus infection
During the 7-year study period, there were 66 patients with 96 S. aureus infections. The characteristics of the infants with S. aureus infection are described in Table 1 . Ninety-one per cent of infants with S. aureus infection were premature and 68% had a birth The S. aureus strains that caused bacteremia proved to be difficult to treat with a median time to a negative repeat blood culture of 4 days (range 2 to 9 days). Forty-six per cent of infants with BSI had metastatic complications with a median time to metastasis of o24 h (range 0 to 5 days). S. aureus was considered to have contributed to an infant's mortality when it occurred within 1 week of death and no other reason for death was evident. Overall mortality of S. aureus bacteremia was 31% with eight infants dying of overwhelming S. aureus sepsis. There were three distinctive S. aureus outbreaks during the 7-year study period (Figure 1 ). There was a MRSA outbreak in 2004 involving seven BSI with two fatal cases and an incidence of 1.88 per 1000 patient-days-at-risk in this pre-mupirocin time. This outbreak involved one primary MRSA strain with an antibiogram reflecting antibiotic resistance to clindamycin, ciprofloxacin and penicillin. The rate of S. aureus infection significantly decreased to 0.40 per 1000 patient-days-at-risk after implementation of intranasal mupirocin in August 2004. Mupirocin was discontinued in February 2005, after which S. aureus infections again increased culminating in another outbreak with a methicillinsensitive S. aureus strain involving 10 BSI with four fatal cases and a rate of 1.42 per 1000 patient-days-at-risk. Mupirocin was reinstated in December 2005 along with other aspects of the comprehensive infection control strategy as previously described, and the rate of S. aureus infection again significantly decreased to 0.33 per 1000 patient-days-at-risk from December 2005 to December 2010. There was a smaller MRSA outbreak involving two BSI at the beginning of 2009 during the mupirocin prophylactic period, which may have been from a mupirocin resistant strain although this was not tested at the time. Overall when comparing the mupirocin prophylactic period with the control period, we had a significant reduction in the rate of S. aureus infection (Po0.0001) with a number needed to treat of 49 and an incidence rate ratio of 0.29 (95% CI: 0.166 to 0.512).
Using the statistical process control U-chart, the outbreaks revealed special cause variation with rates greater than three s.d. above the mean (Figure 2 ). With escalating infection control measures including prophylactic mupirocin and surveillance cultures, our infection rate has exhibited common cause variation with rates below the upper control limit over the last 2 years with a mean rate of infection of 0.2 per 1000 patientdays-at-risk.
S. aureus colonization After routine active surveillance cultures were implemented in April 2008, there were 77 infants found to be colonized with S. aureus. Table 2 summarizes the demographic data of colonized infants. Being outborn or readmitted from home was a highly significant risk factor for colonization (P ¼ 0.0003, OR ¼ 2.64 with 95% CI: 1.54, 4.55). Although historic colonization data during the 2002 outbreak obtained from hospital generated infection control reports revealed an average time to colonization of 3 weeks (data not included), we found that within our study period, more than 50% of the inborn infants who were ever colonized were found to be colonized on admission including a set of twins and a set of triplets with an average time to colonization being 9 days. Half of the infants who were colonized at birth were delivered via cesarean section most with intact membranes. Colonization was significantly associated with extremely low birth weight (P ¼ 0.009, OR ¼ 3.28 with 95% CI: 1.35, 8.00) and extreme prematurity (P ¼ 0.0009, OR ¼ 2.93 with 95% CI: 1.56, 5.52). When adjusting for time to colonization, these results remained highly significant. Of the 77 infants who were found to be colonized, 11 infants developed a S. aureus infection, whereas only 5 infants developed a S. aureus infection in the noncolonized group. Therefore, colonized infants were 82 times more likely to become infected with S. aureus than noncolonized infants.
After starting routine surveillance screening in April 2008, the number of children screened generally varied between 40 and 70 depending on the census of the NICU at that time. We found S. aureus colonization rates initially at 5 to 10% but then as high as Rate (per 1000 patient-days-at-risk)
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DISCUSSION
We report our 7-year experience with long-term universal mupirocin prophylaxis and S. aureus surveillance as part of an escalating quality improvement approach in decreasing S. aureus colonization and infection in our NICU. With the use of prophylactic mupirocin we created a barrier to colonization without inducing mupirocin resistance; and with S. aureus surveillance we were successful in optimizing isolation and cohorting for infants with nasal carriage to prevent ongoing transmission. This is the first study to the author's knowledge that reports the use of longterm, unselective mupirocin prophylaxis within a neonatal ICU. There are only a few published cases in the available literature that report the use of universal prophylactic mupirocin to prevent the spread of S. aureus in a NICU. 3, [16] [17] [18] [19] [20] [21] These studies are summarized in Supplementary Information 3. Aside from these studies that utilized mupirocin during brief periods, we were unable to find literature reporting long-term use of prophylactic intranasal mupirocin for S. aureus colonization prophylaxis in high-risk neonates. We found that with long-term prophylactic mupirocin, we were able to maintain low S. aureus colonization rates, eradicate outbreaks and minimize infection over a sustained period.
Repeated exposure to mupirocin for S. aureus prophylaxis has been shown to induce rapid resistance in certain populations as high as 65%. 22 Other studies report no increase in mupirocin resistance even after long-term exposure. [23] [24] [25] We found during our study period that even after long-term prophylactic mupirocin, we did not have a single case of mupirocin resistance. We currently are testing for only single-level resistance without differentiating high or low-level. High-level mupirocin resistance has been associated with mupirocin decolonization failure, whereas low-level resistance is of unknown clinical significance but may allow for persistent MRSA carriage after decolonization. 26 If we find mupirocin resistance in our population, we may need to make this distinction to differentiate isolates with a potential clinical impact. Additionally, if mupirocin resistance is detected, we may need to alternate with another topical antimicrobial agent to re-gain control. we added active surveillance cultures on admission to our already weekly S. aureus surveillance in order to isolate infants who were colonized at birth. With these escalating infection control measures, our infection rate has exhibited common cause variation with rates below the upper control limt over the last 2 years with a mean rate of infection of 0.2 per 1000 patient-days-at-risk. There is currently no consensus regarding the routine use of S. aureus surveillance in neonates, however, some experts believe that targeted surveillance of high-risk patients is warranted. It is clear that S. aureus surveillance in our high-risk population has been beneficial in further reducing infection rates as in the statistical process control U-chart in (Figure 2 ) since the institution of admission and weekly surveillance screening. Additionally, S. aureus colonization predicted infection with great significance with infections occurring when weekly colonization exceeded 10%. With surveillance screening, escalating colonization rates may warn of a possible outbreak allowing for increased infection control efforts.
The relationship of S. aureus colonization to future disease demonstrates the necessity for a barrier to initial colonization. In the neonate in particular, S. aureus colonization and infection within the NICU are largely thought to be horizontally transmitted from infected or colonized healthcare workers, parents, and breastmilk and not vertically transmitted through rectovaginal MRSA colonization as previously reported. 4, 27, 28 However more recently, studies are reporting early colonization suggesting a greater percentage of infants may be acquiring S. aureus from their mothers. 1 Our data also reflect a trend towards early colonization. However, with 44% of infants found to be colonized at birth born via cesarean section most with intact membranes, this suggests that vertical transmission of S. aureus may still be unlikely. Our hospital does not routinely perform rectovaginal S. aureus surveillance cultures on mothers, but this may be an area of which to focus our future efforts. Another possibility that could account for infants colonized at birth could be the possible contamination of resuscitation equipment by colonized delivery room personnel. Before entering the cesarean section suite, the resuscitation team is required to don hats, gowns, masks, gloves and shoe covers. It is possible that members of the resuscitation team are colonized spreading S. aureus to suction catheters or resuscitation masks during a safety check of the equipment before delivery. With a high level of S. aureus colonization throughout the local community, this translates to a higher risk of transmission to our patients. After prophylaxis with intranasal mupirocin, this acts as a barrier to colonization and therefore these infants may be less likely to have S. aureus growth on subsequent surveillance cultures. We do not routinely screen healthcare workers or resuscitation equipment for S. aureus colonization or contamination, however, if we find that there is continued introduction of S. aureus into our unit in particular of inborn infants on admission, we may need to introduce these practices.
The majority of the inborn infants who were ever colonized were found to be colonized directly on admission without previous exposure to antibiotics. The remaining infants who were colonized after birth, became colonized despite the use of prophylactic twice daily intranasal mupirocin. Although the nares are a common reservoir for S. aureus, other body sites can also harbor Staphylococcus. 29, 30 Although our belief is that compliance with prophylaxis in our unit is high, our speculation as to ongoing nasal colonization during nasal prophylaxis is possibly from ongoing cross contamination from other colonized body sites or that the infants were nasally colonized with an unidentified resistance strain before testing for mupirocin resistance.
Although the simultaneous institution of mupirocin prophylaxis with the Institute of Healthcare Improvement central line bundle and later the institution of surveillance screening limits our ability to attribute the decrease in S. aureus infection to mupirocin alone, the combination of these practices have led to an overall low rate of S. aureus infection. While prophylactic mupirocin was key to eradicating outbreaks and acted as a barrier to colonization, the addition of surveillance screening both on admission and weekly further decreased transmission rates and allowed for greater overall control. This study has several limitations that must be kept in mind when interpreting our findings. Our investigation is limited by its retrospective observational design. This raises the potential for misclassification of S. aureus infections. We were also limited in our statistical analyses by occasional incomplete electronic medical records data for which the patient was excluded from that particular analysis. Additionally, some statistical analyses may be ambiguous as there are several causal pathways to infection/ colonization that are confounded between birth weight, gestational age and length of stay.
CONCLUSION
With hyperendemic rates of S. aureus in our NICU, we implemented the use of prophylactic mupirocin in all NICU infants starting briefly in 2004 and routinely in 2005 to the present day. With this change in practice as part of a comprehensive infection control strategy, we have decreased the rate of S. aureus colonization and dramatically reduced S. aureus infection over a 5-year period. Efforts to prevent S. aureus colonization should have a high priority in the NICU. Given that S. aureus infections in the NICU are often severe and with frequently fatal complications, instituting this and other barrier methods may be an effective strategy in NICUs experiencing problems with S. aureus.
